Skip to main content

PetVivo (NASDAQ: PETV) Receives Initial Regulatory Assessment for Biomatrix Particulate Technology Applications

PetVivo Holdings, Inc., a growing biomedical device firm, has announced the receipt of an initial regulatory assessment for their proprietary Biomatrix Particulate Technology from a Contract Research Organization. This technology promises to revolutionize treatments in both animal and human healthcare sectors.

A Step Closer to the Commercialization of Cutting-edge Medical Devices

The preliminary regulatory assessment paves the way for the approval of diverse indications for the Biomatrix Particulate Technology. The applications range from dermal fillers to tendon and ligament repair, intraarticular injectable devices, urinary incontinence bulking agents, and dental soft tissue augmentation biomaterials. This milestone aligns with PetVivo’s goal to enhance patient lives, both human and animal, through innovative medical solutions.

SPRYNG™: PetVivo’s Pioneer Biomatrix Particulate Technology Product

SPRYNG™ with OsteoCushion™ Technology, the first product to implement the Biomatrix Particulate Technology, has proven successful in treating various joint-related afflictions in animals. The SPRYNG microparticles, sterilized extracellular matrix particles, function as micro-cushions in the joint, helping manage conditions like osteoarthritis and lameness.

Expansion into Human Health Sector

Following the demonstrated success of SPRYNG in treating a multitude of companion animals and horses, PetVivo is eager to expedite the regulatory process for its human products. As PetVivo’s CEO John Lai stated, “We are looking forward to moving one or more products through the regulatory process as quickly as possible so that we can begin commercialization in a number of very large market sectors.”

Upcoming Manufacturing Facility in Edina, Minnesota

In preparation for the development of these new human products, PetVivo is set to inaugurate its advanced manufacturing facility in Edina, Minnesota, by late 2023. The products designed for human use will be manufactured at this state-of-the-art site.

PetVivo Holdings, Inc.: Advancing Veterinary and Human Health

PetVivo is an emerging leader in the field of biomedical device technology, focusing on the manufacturing, commercialization, and licensing of innovative medical devices for companion animals. The company is known for its robust pipeline of seventeen products and a portfolio of nineteen patents, with the intraarticular injection SPRYNG as their lead product, currently available for commercial sale to veterinarians.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit:

The post PetVivo (NASDAQ: PETV) Receives Initial Regulatory Assessment for Biomatrix Particulate Technology Applications appeared first on Spotlight Growth.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.